What's next for cellular immunotherapies?


October 13, 2021 -- CARLSBAD, CA - What's the next step in the development of cellular immunotherapies, particularly for liquid and solid tumors? At this week's Cell & Gene Meeting on the Mesa, Dr. Kanya Rajangam, PhD, of Nkarta Therapeutics explained the latest approaches.

ScienceBoard.net caught up to Rajangam, chief medical officer of Nkarta, shortly after a Wednesday plenary session she participated in. She explained Nkarta's approach on allogeneic NK cell therapy, with a particular focus on making these new therapies available more broadly.

NK cells make up about 20% of the normal lymphocytes in the body and are the backbone of Nkarta's technology. The company has leveraged the natural ability of NK cells to target cancer and augmented it with additional functionality to make it a viable cell therapy, Rajangam said.

Learn more by watching the video below.

Video loading ...


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.